Prediagnosis plasma adiponectin in relation to colorectal cancer risk according to KRAS mutation status

Journal of the National Cancer Institute

Volumn 108, Issue 4, 2016, Pages

  Inamura, Kentaro ^a,b,c   Song, Mingyang ^d   Jung, Seungyoun ^d   Nishihara, Reiko ^a,d   Yamauchi, Mai ^a   Lochhead, Paul ^a,e   Qian, Zhi Rong ^a   Kim, Sun A ^a   Mima, Kosuke ^a   Sukawa, Yasutaka ^a   Masuda, Atsuhiro ^h   Imamura, Yu ^a   Zhang, Xuehong ^a   Pollak, Michael N ^f   Mantzoros, Christos S ^a   Harris, Curtis C ^b   Giovannucci, Edward ^a,d   Fuchs, Charles S ^a   Cho, Eunyoung ^a,g   Chan, Andrew T ^a,e   Wu, Kana ^d   Ogino, Shuji ^a,d   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CANCER INSTITUTE   (Japan)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f MCGILL UNIVERSITY   (Canada)

^g BROWN UNIVERSITY   (United States)

^h Massachusetts General Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ACETYLSALICYLIC ACID; ADIPONECTIN; B RAF KINASE; CALCIUM; FOLIC ACID; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BLOOD SAMPLING; CALORIC INTAKE; CANCER RISK; COLON CARCINOMA; COLORECTAL CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECTUM CARCINOMA; RED MEAT; SMOKING; VITAMIN BLOOD LEVEL; WILD TYPE; BLOOD; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; COMPLICATION; GENETICS; INCIDENCE; MIDDLE AGED; MUTATION; OBESITY; ODDS RATIO; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; UNITED STATES;

ADIPONECTIN; ADULT; AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; OBESITY; ODDS RATIO; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84964894113     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv363     Document Type: Article

References (62)

1. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270(45):26746- 26749.
2. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271(18):10697-10703.
3. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784-1792.
4. Song M, Zhang X, Wu K, et al. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: A prospective study. Cancer Prev Res (Phila). 2013;6(9):875-885.
5. Wei EK, Giovannucci E, Fuchs CS, et al. Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. J Natl Cancer Inst. 2005;97(22):1688-1694.
6. Aleksandrova K, Boeing H, Jenab M, et al. Total and high-molecular weight adiponectin and risk of colorectal cancer: The european prospective investigation into cancer and nutrition study. Carcinogenesis. 2012;33(6):1211-1218.
7. Xu XT, Xu Q, Tong JL, et al. Meta-Analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J Dig Dis. 2011;12(4):234-244.
8. Otake S, Takeda H, Suzuki Y, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: Evidence for participation of insulin resistance. Clin Cancer Res. 2005;11(10):3642-3646.
9. Yamaji T, Iwasaki M, Sasazuki S, et al. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res. 2010;70(13):5430- 5437.
10. Barb D, Williams CJ, Neuwirth AK, et al. Adiponectin in relation to malignancies: A review of existing basic research and clinical evidence. Am J Clin Nutr. 2007;86(3):s858-s866.
11. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012;12(6):621-628.
12. Rosty C, Young JP, Walsh MD, et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol. 2013;26(6):825-834.
13. Imamura Y, Lochhead P, Yamauchi M, et al. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer. 2014;13(1):135.
14. Eklof V, Wikberg ML, Edin S, et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer. 2013;108(10):2153-2163.
15. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-337.
16. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757-1765.
17. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304(16):1812- 1820.
18. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532-536.
19. Slattery ML, Curtin K, Anderson K, et al. Associations between dietary intake and Ki-ras mutations in colon tumors: A population-based study. Cancer Res. 2000;60(24):6935-6941.
20. Slattery ML, Anderson K, Curtin K, et al. Lifestyle factors and Ki-ras mutations in colon cancer tumors. Mutat Res. 2001;483(1-2):73-81.
21. Slattery ML, Curtin K, Wolff RK, et al. Diet, physical activity, and body size associations with rectal tumor mutations and epigenetic changes. Cancer Causes Control. 2010;21(8):1237-1245.
22. Colussi D, Brandi G, Bazzoli F, et al. Molecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention. Int J Mol Sci. 2013;14(8):16365-16385.
23. Rosty C, Young JP, Walsh MD, et al. PIK3CA activating mutation in colorectal carcinoma: Associations with molecular features and survival. PLoS One. 2013;8(6):e65479.
24. Phipps AI, Buchanan DD, Makar KW, et al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1792-1798.
25. Reimers MS, Zeestraten EC, Kuppen PJ, et al. Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf). 2013;1(3):166-183.
26. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596-1606.
27. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369(12):1095-1105.
28. Yamauchi M, Lochhead P, Morikawa T, et al. Colorectal cancer: A tale of two sides or a continuum? Gut. 2012;61(6):794-797.
29. Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61(6):847- 854.
30. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005;7(3):413-421.
31. Ogino S, Kawasaki T, Kirkner GJ, et al. CpG island methylator phenotypelow (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn. 2006;8(5):582-588.
32. Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: Relationship with genetic and epigenetic alterations. Neoplasia. 2008;10(6):534-541.
33. Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012;18(8):2257-2268.
34. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics. 1995;51(2):524-532.
35. Rosner B, Glynn RJ, Tamimi RM, et al. Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. Am J Epidemiol. 2013;178(2):296-308.
36. Sugiyama M, Takahashi H, Hosono K, et al. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol. 2009;34(2):339-344.
37. Kim AY, Lee YS, Kim KH, et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- And -R2-mediated AMPK activation. Mol Endocrinol. 2010;24(7):1441-1452.
38. Brakenhielm E, Veitonmaki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004;101(8):2476-2481.
39. Byeon JS, Jeong JY, Kim MJ, et al. Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer. 2010;127(12):2758-2767.
40. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: A systematic review. Br J Cancer. 2006;94(9):1221-1225.
41. Gonsalves WI, Mahoney MR, Sargent DJ, et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014;106(7):pii: dju106.
42. Noreen F, Roosli M, Gaj P, et al. Modulation of age- And cancer-Associated DNA methylation change in the healthy colon by aspirin and lifestyle. J Natl Cancer Inst. 2014;106(7):pii: dju161.
43. Barrow TM, Michels KB. Epigenetic epidemiology of cancer. Biochem Biophys Res Commun. 2014;455(1-2):70-83.
44. Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015;148(1):77-87 e72.
45. Buchanan DD, Win AK, Walsh MD, et al. Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases. Cancer Epidemiol Biomarkers Prev. 2013;22(5):917-926.
46. Mehta RS, Song M, Bezawada N, et al. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. J Natl Cancer Inst. 2014;106(4):dju016.
47. Ng JM, Yu J. Promoter Hypermethylation of Tumour Suppressor Genes as Potential Biomarkers in Colorectal Cancer. Int J Mol Sci. 2015;16(2):2472-2496.
48. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: The evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102(6):365-367.
49. Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: An emerging transdisciplinary and interdisciplinary field. Gut. 2011;60(3):397-411.
50. Bishehsari F, Mahdavinia M, Vacca M, et al. Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol. 2014;20(20):6055-6072.
51. Epplein M, Bostick RM, Mu L, et al. Challenges and opportunities in international molecular cancer prevention research: An ASPO Molecular Epidemiology and the Environment and International Cancer Prevention Interest Groups Report. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2613-2617.
52. Campbell PT, Deka A, Briggs P, et al. Establishment of the cancer prevention study II nutrition cohort colorectal tissue repository. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2694-2702.
53. Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem. 2003;49(4):650-652.
54. Huebinger RM, Xiao G, Wilhelmsen KC, et al. Comparison of protein concentrations in serum versus plasma from Alzheimer's patients. Adv Alzheimer Dis. 2012;1(3):51-58.
55. Neumeier M, Weigert J, Schaffler A, et al. Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol. 2006;79(4):803-808.
56. Joshi RK, Lee SA. Obesity related adipokines and colorectal cancer: A review and meta-Analysis. Asian Pac J Cancer Prev. 2014;15(1):397-405.
57. Bluher M, Brennan AM, Kelesidis T, et al. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care. 2007;30(2):280-285.
58. Wolf AM, Hunter DJ, Colditz GA, et al. Reproducibility and validity of a selfadministered physical activity questionnaire. Int J Epidemiol. 1994;23(5):991-999.
59. Rimm EB, Giovannucci EL, Stampfer MJ, et al. Reproducibility and validity of an expanded self-Administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol. 1992;135(10):1114- 1126; discussion 1127-1136.
60. Willett WC. Nutritional Epidemiology. Third ed. New York: Oxford University Press; 2012.
61. Tillmans LS, Vierkant RA, Wang AH, et al. Associations between cigarette smoking, hormone therapy, and folate intake with incident colorectal cancer by TP53 protein expression level in a population-based cohort of older women. Cancer Epidemiol Biomarkers Prev. 2014;23(2):350-355.
62. Campbell PT, Newton CC, Newcomb PA, et al. Association between Body Mass Index and Mortality for Colorectal Cancer Survivors: Overall and by Tumor Molecular Phenotype. Cancer Epidemiol Biomarkers Prev. 2015;24(8):1229-1238.